Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Alternate Therapies and Proteomics/Genomics Studies of Cancer
share announcement

Alternate Therapies and Proteomics/Genomics Studies of Cancer

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 7734

Special Issue Editor

Prof. Dr. Raji Sundararajan

E-Mail Website
Guest Editor
School of Engineering Technology, Purdue University, Knoy Hall of Technology, West Lafayette, IN 47907, USA
Interests: artificial intelligence; machine learning; neural networks; deep learning; obesity; diabetes; cancer; other diseases; pathology; drug discovery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues，

The 9.8 million cancer deaths in 2018 (a death every 3.5 seconds) indicate that the current standard of treatment for cancer is inadequate. There are inoperable, recurring, advanced, chemo- and radiation-resistant tumors that beg for alternate treatment. The key to successful development and effective application of various anticancer agents is a better understanding of the various pathways and of resistance mechanisms that may develop. This calls for more knowledge at the molecular level. Proteomic and genomic studies help us to gain insights into the various proteins and genes, their up- and down-regulations, and their outcomes on the pathways. Proteins in the receptors, cell membranes, and elsewhere affect the efficacy of drugs and their pathways. Knowledge and analysis of the genome sequence allows enhanced understanding of genetic alterations underlying the origin and nature of tumors.

Application of alternate therapies and cell and molecular studies of cancer using proteome and genome principles will open a number of gateways that can throw more light on various details unknown or unexplored yet and which have the potential to be transformed to clinical applications. To this end, in this Special Issue, we cordially invite scholarly original research articles and reviews on the various alternate therapies for cancers and the effective use of proteomic and genomic studies in uncovering additional details that could be relevant for clinical practices as well as fundamental understanding.

Prof. Dr. Raji Sundararajan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • proteomics
  • genomics
  • pathways
  • alternate therapies

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1712 KiB  
Article
Electrochemotherapy Modulates Mammary Tumor Growth in Rats on a Western Diet Supplemented with Curcumin
by Raji Sundararajan, Lakshya Mittal and Ignacio G. Camarillo
Biomedicines 2020, 8(11), 498; https://doi.org/10.3390/biomedicines8110498 - 13 Nov 2020
Cited by 3 | Viewed by 3062
Abstract
In the US, every 12 min, six women are diagnosed with breast cancer and one dies. This highlights a critical need for developing alternate therapies using natural compounds, which are cost effective and with less side effects. Curcumin, the yellow pigment of turmeric [...] Read more.
In the US, every 12 min, six women are diagnosed with breast cancer and one dies. This highlights a critical need for developing alternate therapies using natural compounds, which are cost effective and with less side effects. Curcumin, the yellow pigment of turmeric has been found to suppress initiation, progression, and metastasis of a variety of tumors. Multiple clinical trials highlight the efficacy of curcumin in treating breast cancer and other diseases. Our in vitro studies have demonstrated that the electrical pulse (EP) application can further enhance the effectiveness of curcumin against breast cancer cells in a therapy called electrochemotherapy (ECT). In a direct extension of these results, we studied the effect of ECT coupled with intratumoral curcumin administration (EP+Cur) on N-methyl-N-nitrosourea (MNU) induced mammary tumors in female Sprague Dawley rats. Beginning at the weaning and throughout the study, rats were fed either western diet (West) or western diet, supplemented with 1% curcumin (W+Cur). Our results showed that EP+Cur treatment led to a reduced growth rate in rats fed with W+Cur diet compared to West diet (57.14% vs. 16.67% in West diet). These results provide a foundation for further studies towards utilizing it in clinical practice. Full article
(This article belongs to the Special Issue Alternate Therapies and Proteomics/Genomics Studies of Cancer)
►▼ Show Figures

Figure 1

12 pages, 1005 KiB  
Article
COL2A1 Is a Novel Biomarker of Melanoma Tumor Repopulating Cells
by Bhavana Talluri, Kshitij Amar, Michael Saul, Tasnim Shireen, Vjollca Konjufca, Jian Ma, Taekjip Ha and Farhan Chowdhury
Biomedicines 2020, 8(9), 360; https://doi.org/10.3390/biomedicines8090360 - 18 Sep 2020
Cited by 8 | Viewed by 4047
Abstract
Soft 3D-fibrin-gel selected tumor repopulating cells (TRCs) from the B16F1 melanoma cell line exhibit extraordinary self-renewal and tumor-regeneration capabilities. However, their biomarkers and gene regulatory features remain largely unknown. Here, we utilized the next-generation sequencing-based RNA sequencing (RNA-seq) technique to discover novel biomarkers [...] Read more.
Soft 3D-fibrin-gel selected tumor repopulating cells (TRCs) from the B16F1 melanoma cell line exhibit extraordinary self-renewal and tumor-regeneration capabilities. However, their biomarkers and gene regulatory features remain largely unknown. Here, we utilized the next-generation sequencing-based RNA sequencing (RNA-seq) technique to discover novel biomarkers and active gene regulatory features of TRCs. Systems biology analysis of RNA-seq data identified differentially expressed gene clusters, including the cell adhesion cluster, which subsequently identified highly specific and novel biomarkers, such as Col2a1, Ncam1, F11r, and Negr1. We validated the expression of these genes by real-time qPCR. The expression level of Col2a1 was found to be relatively low in TRCs but twenty-fold higher compared to the parental control cell line, thus making the biomarker very specific for TRCs. We validated the COL2A1 protein by immunofluorescence microscopy, showing a higher expression of COL2A1 in TRCs compared to parental control cells. KEGG pathway analysis showed the JAK/STAT, hypoxia, and Akt signaling pathways to be active in TRCs. Besides, the aerobic glycolysis pathway was found to be very active, indicating a typical Warburg Effect on highly tumorigenic cells. Together, our study revealed highly specific biomarkers and active cell signaling pathways of melanoma TRCs that can potentially target and neutralize TRCs. Full article
(This article belongs to the Special Issue Alternate Therapies and Proteomics/Genomics Studies of Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop